FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213653721> ?p ?o ?g. }

• W3213653721 endingPage "2285" @default.
• W3213653721 startingPage "2285" @default.
• W3213653721 abstract "Abstract Background: trALL is an important secondary primary malignancy (SPM) that has recently been appreciated. While patients (pts) with MM have an 8%-17% risk of developing an SPM while on lenalidomide (R) maintenance following autologous stem cell transplant (ASCT), trALL has been rarely observed. Little is known about the characteristics of trALL in pts with MM compared to pts who had other malignancies prior to the development of trALL. We define tALL as any prior exposure to cytotoxic chemotherapy and/or radiation for another malignancy, and herein, we report a comparative analysis of characteristics and outcomes of pts with trALL with and without MM from the Mayo Clinic Cancer Center (MCCC). Methods: We performed a systematic search in the 3-site MCCC registry and included all pts diagnosed and received at least 1 cycle of ALL-directed therapy and/or underwent allogeneic transplantation (AlloHCT) for ALL between 2007-2020. All cases of trALL in this series are B-ALL. Comparisons of characteristics between trALL patients with and without MM were made using a Wilcoxon rank sum test (continuous variables) or Fisher's exact test (categorical variables). Time-to-event variables were compared using unadjusted Cox proportional hazards regression models. Results: 70 trALL pts (14 MM [20%], 56 non-MM [80%]) were identified during the study period. The median age at trALL diagnosis was 63.9 (range 47-71) for MM pts and 63.1 (range 18.2-84) for non-MM pts. Median follow-up from trALL diagnosis was 1.42 years (range 0.02-10.6 years). The most common prior non-MM malignancies among tALL pts were breast (28.6%), lymphoma (17.9%), myeloid (17.9%), and GU/GYN (14.3%). Amongst the 14 MM pts, 100% (n=10) had ISS-I disease, 8 (57%) had IgG K MM, 1 (n=10) had high risk cytogenetics, 8 (57.1%) received R-based induction , 4 (28.6%) received CyBorD induction, 4(28.6%) received VRD induction, 3 (21.4%) received RD induction. 10 (71.4%) pts were actively on R when they developed trALL, 8 (57.1%) pts received prior ASCT. The median time to develop trALL following ASCT for MM was 46.3 months (m), (95% CI 20.4-67.6), 12 (85.7%) pts received R maintenance with a median duration of 53m (95% CI 16.9-121). The median time to develop trALL after initiation of R maintenance was 61.2m (95% CI 16.9-123.4). The most common trALL induction regimen received was HyperCVAD which was used in 71.4% of MM pts and 51.8% of non-MM pts. In comparison to non-MM pts, MM patients had a significantly lower WBC at diagnosis (Median: 2.0 vs. 5.8, P=0.005),no t(9;22) BCR/ABL1 cytogenetics (0.0% vs. 35.7%, P=0.008), a higher frequency of hypodiploid/near-triploid (Ho-Tri) cytogenetics (42.9% vs. 12.5%, P=0.009), and a lower frequency of prior radiation therapy (7.1% vs. 44.6%, P=0.012). MM pts had a higher frequency of AlloHCT for trALL (71.4% vs. 42.9%, P=0.075) and were more commonly in complete response (CR) at transplant (100.0% vs. 70.8%, P=0.078). No trALL in MM pts were Ph-like ALL. There was a statistically significant difference in time to development of trALL between previous malignancy locations (P=0.018), with GU/GYN (Median: 9 years) having the longest time and myeloid (Median: 3 years) having the shortest time; MM was 6 years. In the overall pt cohort, 56 (80%) pts achieved a complete response after induction and 60% (n=25) were minimal residual disease (MRD)+ after induction. Pts with MM had a significantly lower likelihood of being MRD+ after induction (OR=0.09, P=0.015). Overall, 24.3% of pts relapsed after induction therapy for trALL; 39 (55.5%) died after trALL diagnosis including 43% (n=35) who died after AlloHCT. Although pts with MM tended to have better outcomes compared to non-MM trALL pts in terms of overall survival after trALL diagnosis (Figure 1A), survival after AlloHCT (Figure 1B), relapse rate after trALL diagnosis and non-relapse mortality after AlloHCT, none of these findings were statistically significant in this small cohort (Figure 1C). Conclusion: trALL is a unique SPM that can occur in pts with MM. It is associated with Ho-Tri cytogenetics and is BCR/ABL1 negative. The majority of MM pts that developed trALL had undergone prior ASCT and were on R maintenance when they developed trALL. Despite being more likely to have adverse cytogenetics features, MM-associated trALL has similar survival compared to non-MM-associated trALL which speaks to the poor survival outcomes of this SPM. Further research on trALL in MM pts is merited. Figure 1 Figure 1. Disclosures Litzow: Amgen: Research Funding; Pluristem: Research Funding; AbbVie: Research Funding; Actinium: Research Funding; Astellas: Research Funding; Omeros: Other: Advisory Board; Jazz: Other: Advisory Board; Biosight: Other: Data monitoring committee. Bergsagel: Janssen: Consultancy. Fonseca: Scientific Advisory Board: Adaptive Biotechnologies: Membership on an entity's Board of Directors or advisory committees; Caris Life Sciences: Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy; Patent: Prognosticaton of myeloma via FISH: Patents & Royalties; Bayer: Consultancy; Takeda: Consultancy; Celgene: Consultancy; Amgen: Consultancy; BMS: Consultancy; Mayo Clinic in Arizona: Current Employment; Juno: Consultancy; Kite: Consultancy; Aduro: Consultancy; OncoTracker: Consultancy, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy; Novartis: Consultancy; Merck: Consultancy; Sanofi: Consultancy; Pharmacyclics: Consultancy; Janssen: Consultancy. Dispenzieri: Takeda: Research Funding; Alnylam: Research Funding; Pfizer: Research Funding; Oncopeptides: Consultancy; Sorrento Therapeutics: Consultancy; Janssen: Consultancy, Research Funding. Murthy: CRISPR Therapeutics: Research Funding. Ailawadhi: GSK: Consultancy, Research Funding; Sanofi: Consultancy; Pharmacyclics: Consultancy, Research Funding; Takeda: Consultancy; Medimmune: Research Funding; Xencor: Research Funding; Genentech: Consultancy; Janssen: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Cellectar: Research Funding; Beigene: Consultancy; BMS: Consultancy, Research Funding; AbbVie: Consultancy; Karyopharm: Consultancy; Ascentage: Research Funding. Foran: actinium: Research Funding; taiho: Honoraria; bms: Honoraria; servier: Honoraria; pfizer: Honoraria; novartis: Honoraria; OncLive: Honoraria; abbvie: Research Funding; boehringer ingelheim: Research Funding; takeda: Research Funding; trillium: Research Funding; aptose: Research Funding; revolution medicine: Honoraria; syros: Honoraria; sanofi aventis: Honoraria; certara: Honoraria; gamida: Honoraria; kura: Research Funding; h3bioscience: Research Funding; aprea: Research Funding; sellas: Research Funding; stemline: Research Funding." @default.
• W3213653721 created "2021-11-22" @default.
• W3213653721 creator A5003015868 @default.
• W3213653721 creator A5013824370 @default.
• W3213653721 creator A5017327825 @default.
• W3213653721 creator A5023628069 @default.
• W3213653721 creator A5031027678 @default.
• W3213653721 creator A5035051206 @default.
• W3213653721 creator A5044589378 @default.
• W3213653721 creator A5044719918 @default.
• W3213653721 creator A5049552841 @default.
• W3213653721 creator A5055281451 @default.
• W3213653721 creator A5055467873 @default.
• W3213653721 creator A5064856519 @default.
• W3213653721 creator A5065354370 @default.
• W3213653721 creator A5072502164 @default.
• W3213653721 creator A5085360755 @default.
• W3213653721 creator A5089383415 @default.
• W3213653721 creator A5091287816 @default.
• W3213653721 date "2021-11-05" @default.
• W3213653721 modified "2023-10-05" @default.
• W3213653721 title "Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM)" @default.
• W3213653721 doi "https://doi.org/10.1182/blood-2021-151574" @default.
• W3213653721 hasPublicationYear "2021" @default.
• W3213653721 type Work @default.
• W3213653721 sameAs 3213653721 @default.
• W3213653721 citedByCount "0" @default.
• W3213653721 crossrefType "journal-article" @default.
• W3213653721 hasAuthorship W3213653721A5003015868 @default.
• W3213653721 hasAuthorship W3213653721A5013824370 @default.
• W3213653721 hasAuthorship W3213653721A5017327825 @default.
• W3213653721 hasAuthorship W3213653721A5023628069 @default.
• W3213653721 hasAuthorship W3213653721A5031027678 @default.
• W3213653721 hasAuthorship W3213653721A5035051206 @default.
• W3213653721 hasAuthorship W3213653721A5044589378 @default.
• W3213653721 hasAuthorship W3213653721A5044719918 @default.
• W3213653721 hasAuthorship W3213653721A5049552841 @default.
• W3213653721 hasAuthorship W3213653721A5055281451 @default.
• W3213653721 hasAuthorship W3213653721A5055467873 @default.
• W3213653721 hasAuthorship W3213653721A5064856519 @default.
• W3213653721 hasAuthorship W3213653721A5065354370 @default.
• W3213653721 hasAuthorship W3213653721A5072502164 @default.
• W3213653721 hasAuthorship W3213653721A5085360755 @default.
• W3213653721 hasAuthorship W3213653721A5089383415 @default.
• W3213653721 hasAuthorship W3213653721A5091287816 @default.
• W3213653721 hasBestOaLocation W32136537211 @default.
• W3213653721 hasConcept C126322002 @default.
• W3213653721 hasConcept C141071460 @default.
• W3213653721 hasConcept C143998085 @default.
• W3213653721 hasConcept C191093355 @default.
• W3213653721 hasConcept C2776063141 @default.
• W3213653721 hasConcept C2776364478 @default.
• W3213653721 hasConcept C2779050716 @default.
• W3213653721 hasConcept C2779399171 @default.
• W3213653721 hasConcept C2911091166 @default.
• W3213653721 hasConcept C50382708 @default.
• W3213653721 hasConcept C71924100 @default.
• W3213653721 hasConceptScore W3213653721C126322002 @default.
• W3213653721 hasConceptScore W3213653721C141071460 @default.
• W3213653721 hasConceptScore W3213653721C143998085 @default.
• W3213653721 hasConceptScore W3213653721C191093355 @default.
• W3213653721 hasConceptScore W3213653721C2776063141 @default.
• W3213653721 hasConceptScore W3213653721C2776364478 @default.
• W3213653721 hasConceptScore W3213653721C2779050716 @default.
• W3213653721 hasConceptScore W3213653721C2779399171 @default.
• W3213653721 hasConceptScore W3213653721C2911091166 @default.
• W3213653721 hasConceptScore W3213653721C50382708 @default.
• W3213653721 hasConceptScore W3213653721C71924100 @default.
• W3213653721 hasIssue "Supplement 1" @default.
• W3213653721 hasLocation W32136537211 @default.
• W3213653721 hasOpenAccess W3213653721 @default.
• W3213653721 hasPrimaryLocation W32136537211 @default.
• W3213653721 hasRelatedWork W2033089666 @default.
• W3213653721 hasRelatedWork W2033205295 @default.
• W3213653721 hasRelatedWork W2049717104 @default.
• W3213653721 hasRelatedWork W2060588247 @default.
• W3213653721 hasRelatedWork W2128084036 @default.
• W3213653721 hasRelatedWork W2419626681 @default.
• W3213653721 hasRelatedWork W2790917916 @default.
• W3213653721 hasRelatedWork W3044326410 @default.
• W3213653721 hasRelatedWork W3207199099 @default.
• W3213653721 hasRelatedWork W4281628749 @default.
• W3213653721 hasVolume "138" @default.
• W3213653721 isParatext "false" @default.
• W3213653721 isRetracted "false" @default.
• W3213653721 magId "3213653721" @default.
• W3213653721 workType "article" @default.